Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 3/20 | 0.31 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397113 | 0.87 | PIK3CD (0.45) | PIK3CDPIK3CBPIK3CAPGR | |
| SCHEMBL17397110 | 0.85 | PIK3CD (0.43) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL17397077 | 0.84 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CATP53 | |
| SCHEMBL17397136 | 0.79 | PIK3CD (0.37) | PIK3CDPIK3CBPIK3CANPC1RAB9A | |
| SCHEMBL17397070 | 0.78 | PIK3CD (0.48) | PIK3CDPIK3CBPGRGNRHR | |
| SCHEMBL17397124 | 0.76 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CAGNRHR | |
| SCHEMBL17401125 | 0.75 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL17401123 | 0.75 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL18837509 | 0.75 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL17397109 | 0.75 | PIK3CD (0.43) | PIK3CDPIK3CBPIK3CAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3164400-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | Lupin Limited (IN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | PIK3CD 5/4885PIK3CB 14/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.